România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

ebewe pharma ges.m.b.h. nfg. kg - austria - fluorouracilum - conc. pt. sol. inj./perf. - 50mg/ml - antimetaboliti analogi ai bazelor pirimidinice

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

ebewe pharma gmbh nfg. kg - concentrat pentru solutie perfuzabila - 250 mg/5 ml

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

ebewe pharma gmbh nfg. kg - concentrat pentru solutie perfuzabila - 500 mg/10 ml

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

accord healthcare limited - marea britanie - fluorouracilum - sol. inj. sau perf. - 50mg/ml - antimetaboliti analogi ai bazelor pirimidinice

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

accord healthcare polska sp. z.o.o. - polonia - fluorouracilum - sol. inj. sau perf. - 50mg/ml - antimetaboliti analogi ai bazelor pirimidinice

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

accord healthcare limited - marea britanie - fluorouracilum - sol. inj. sau perf. - 50mg/ml - antimetaboliti analogi ai bazelor pirimidinice

Uniunea Europeană - română - EMA (European Medicines Agency)

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - imunostimulante, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

ebewe pharma ges.m.b.h. nfg. kg - austria - topotecamum - conc. pt. sol. perf. - 1mg/ml - alte antineoplazice alte antineoplazice

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

ebewe pharma ges.m.b.h nfg. kg - austria - oxaliplatinum - conc. pt. sol. perf. - 5 mg/ml - alte antineoplazice compusi de platina

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

ebewe pharma ges.m.b.h nfg. kg - austria - gemcitabinum - conc. pt. sol. perf. - 40mg/ml - antimetaboliti analogi ai bazelor pirimidinice